Monoclonal antibody and method and kit for immunoassay of soluble human ST2
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07K-016/28
C07K-016/18
C12N-005/20
G01N-033/543
G01N-033/535
G01N-033/577
출원번호
US-0243949
(2002-09-16)
우선권정보
JP-2000-077383(2000-03-21)
발명자
/ 주소
Tominaga,Shin ichi
Arai,Takao
Kuroiwa,Kenji
Oshikawa,Katsuhisa
출원인 / 주소
Tominaga,Shin ichi
Arai,Takao
Kuroiwa,Kenji
Oshikawa,Katsuhisa
대리인 / 주소
Armstrong, Kratz, Quintos, Hanson &
인용정보
피인용 횟수 :
33인용 특허 :
2
초록▼
A method for determining a soluble human ST2 in a sample conveniently at a high sensitivity and an assay kit are provided. By an immunological method comprising a step for bringing a sample into contact with an immobilized antibody formed by binding to an insoluble support a first anti-human ST2 ant
A method for determining a soluble human ST2 in a sample conveniently at a high sensitivity and an assay kit are provided. By an immunological method comprising a step for bringing a sample into contact with an immobilized antibody formed by binding to an insoluble support a first anti-human ST2 antibody which binds specifically to a non-denatured human ST2, a step for labelling a first reaction product generated in the previous step by reacting said first reaction product with a second anti-human ST2 antibody which binds specifically to a non-denatured human ST2 by recognizing a site different from the site on ST2 where said first anti-human ST2 antibody binds and which is labelled with a label, and a step for determining the amount of the label on said first reaction product which has been labelled, a soluble human ST2 in a sample is determined. In addition, a recombinant ST2 is employed as a standard to prepare a calibration curve, based on which the ST2 in a sample is quantified.
대표청구항▼
What is claimed is: 1. A monoclonal antibody which binds specifically to a non-denatured human ST2 produced by a hybridoma which is designated by deposition number FERM ABP-10190, FERM ABP-10189, or FERM ABP-10191. 2. A hybridoma which produces the monoclonal antibody according to claim 1. 3.
What is claimed is: 1. A monoclonal antibody which binds specifically to a non-denatured human ST2 produced by a hybridoma which is designated by deposition number FERM ABP-10190, FERM ABP-10189, or FERM ABP-10191. 2. A hybridoma which produces the monoclonal antibody according to claim 1. 3. A hybridoma having deposition number FERM ABP-10190, FERM ABP-10189, or FERM ABP-10191. 4. A method for determining a soluble human ST2 comprising determining human ST2 in a sample immunologically1 comprising: contacting said sample with the monoclonal antibody according to claim 1; and determining formation of an immunological complex between the antibody and the ST2 in the sample. 5. An immunological method for determining soluble human ST2, comprising steps a) to c): a) bringing a sample into contact with an immobilized antibody formed by binding to an insoluble support a first anti-human ST2 antibody which binds specifically to a non-denatured human ST2 to form a first reaction product; b) labeling said first reaction product by reacting said first reaction product with a second labeled anti-human ST2 antibody which binds specifically to a non-denatured human ST2 by recognizing a site different from a site on ST2 where said first anti-human ST2 antibody binds to form a labeled first reaction product; and, c) determining an amount of label on said labeled first reaction product, the amount of label being indicative of soluble ST2 amount in the sample, wherein said first anti-human ST2 antibody or said second anti-human ST2 antibody is a monoclonal antibody produced by one or more hybridomas selected from the group consisting of hybridomas designated by deposition numbers FERM ABP-10190, FERM ABP-10189, or FERM ABP-10191. 6. The immunological method for determining soluble human ST2 in a sample according to claim 5, further comprising steps d) to g): d) reacting said immobilized antibody with a soluble human ST2 as a standard to form a second reaction product; e) labeling said second reaction product by reacting said second reaction product with said second labeled anti-human ST2 antibody to form a labeled second reaction product; f) preparing a calibration curve by determining the amount of label on said labeled second reaction product; and, g) quantifying soluble human ST2 in said sample from the amount of label on said labeled first reaction product, and said calibration curve. 7. An immunological method for determining a soluble human ST2 according to claim 6 wherein said soluble human ST2 as a standard is a recombinant human ST2. 8. An immunological method for determining soluble human ST2, comprising steps a) to c): a bringing a sample into contact with an immobilized antibody formed by binding to an insoluble support a first anti-human ST2 antibody which binds specifically to a non-denatured human ST2 to form a first reaction product; b) labeling said first reaction product by reacting said first reaction product with a second labeled anti-human ST2 antibody which binds specifically to a non-denatured human ST2 by recognizing a site different from a site on ST2 where said first anti-human ST2 antibody binds to form a labeled first reaction product; and, c) determining an amount of label on said labeled first reaction product, the amount of label being indicative of soluble ST2 amount in the sample, wherein said first anti-human ST2 antibody is a monoclonal antibody produced by one or two hybridomas selected from the group consisting of hybridomas designated by deposition numbers FERM ABP-10190, FERM ABP-10189, or FERM ABP-10191, and said second anti-human ST2 antibody is a monoclonal antibody produced by one or two hybridomas which are not selected in said group. 9. An immunological method for determining soluble human ST2, comprising steps a) to c): a) bringing a sample into contact with an immobilized antibody formed by binding to an insoluble support a first anti-human ST2 antibody which binds specifically to a non-denatured human ST2 to form a first reaction product; b) labeling said first reaction product by reacting said first reaction product with a second labeled anti-human ST2 antibody which binds specifically to a non-denatured human ST2 by recognizing a site different from a site on ST2 where said first anti-human ST2 antibody binds to form a labeled first reaction product; and, c) determining an amount of label on said labeled first reaction product, the amount of label being indicative of soluble ST2 amount in the sample. wherein said first anti-human ST2 antibody is a monoclonal antibody produced by one or more hybridomas designated by deposition number FERM ABP-10190 or FERM ABP-10191, and said second anti-human ST2 antibody is a monoclonal antibody produced by the hybridoma designated by deposition number FERM ABP-10189. 10. An immunoassay kit for determining a soluble human ST2 comprising a monoclonal antibody which binds specifically to a non-denatured human ST2 produced by a hybridoma which is designated by deposition number FERM ABP-10190, FERM ABP-10189, or FERM ABP-10191. 11. The immunoassay kit according to claim 10 wherein said monoclonal antibody is one or more monoclonal antibodies produced by one or more hybridomas selected from the group consisting of hybridomas designated by deposition numbers FERM ABP-10190, FERM ABP-10189, or FERM ABP-10191. 12. An immunoassay kit for determining soluble human ST2, comprising: a first anti-human ST2 antibody which binds specifically to a non-denatured human ST2; a second anti-human ST2 antibody which binds specifically to the non-denatured human ST2 by recognizing a site different from the site where said first anti-human ST2 antibody binds and which is labeled with a label; and, a soluble human ST2 as a standard, wherein said first anti-human ST2 antibody or said second anti-human ST2 antibody is a monoclonal antibody produced by one or more hybridomas selected from the group consisting of hybridomas designated by deposition numbers FERM ABP-10190, FERM ABP-10189, or FERM ABP-10191. 13. The immunoassay kit for determining soluble human ST2 according to claim 12, wherein said soluble human ST2 as a standard is a recombinant human ST2. 14. An immunoassay kit for determining soluble human ST2, comprising: a first anti-human ST2 antibody which binds specifically to a non-denatured human ST2; a second anti-human ST2 antibody which binds specifically to the non-denatured human ST2 by recognizing a site different from the site where said first anti-human ST2 antibody binds and which is labeled with a label; and, a soluble human ST2 as a standard, wherein said first anti-human ST2 antibody is a monoclonal antibody produced by one or more hybridomas selected from the group consisting of hybridomas designated by deposition numbers FERM ABP-10190, FERM ABP-10189, or FERM ABP-10191, and wherein said second anti-human ST2 antibody is a monoclonal antibody produced by one or more hybridomas which are not selected in said group. 15. An immunoassay kit for determining soluble human ST2, comprising: a first anti-human ST2 antibody which binds specifically to a non-denatured human ST2; a second anti-human ST2 antibody which binds specifically to the non-denatured human ST2 by recognizing a site different from the site where said first anti-human ST2 antibody binds and which is labeled with a label; and, a soluble human ST2 as a standard, wherein said first anti-human ST2 antibody is a monoclonal antibody produced by one or more hybridomas designated by deposition numbers FERM ABP-10190 or FERM ABP-10191, and wherein said second anti-human ST2 antibody is a monoclonal antibody produced by the hybridoma designated by the deposition number FERM ABP-10189. 16. An immunological method for determining soluble human ST2 in a sample, comprising: reacting a sample with an immobilized antibody formed by binding to an insoluble support a first monoclonal ST2 antibody produced by a hybridoma designated by deposition number FERM ABP-10190 and which binds specifically to a human ST2 thereby binding human ST2 present in said sample to form bound ST2, reacting said bound ST2 with a labeled antibody formed by labeling a second monoclonal antibody produced by a hybridoma designated by deposition number FERM ABP-10189 to form a labeled first reaction product; preparing a calibration curve comprising reacting said immobilized antibody with a recombinant human ST2, to form bound standard ST2 reacting said bound standard ST2 with said labeled antibody to form a labeled second reaction product; measuring the amount of label on said labeled second reaction product to produce a calibration curve; and, quantifying soluble human ST2 contained in said sample from the amount of label on said first labeled reaction product, and said calibration curve. 17. An immunoassay kit for determining soluble human ST2 comprising: an immobilized antibody formed by binding to an insoluble support a first monoclonal antibody which is produced by a hybridoma designated by deposition number FERM ABP-10190 and which binds specifically to a human ST2; a labeled antibody formed by labeling a second monoclonal antibody produced by a hybridoma designated by deposition number FERM ABP-10189; and, a recombinant ST2 as a standard.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (2)
David Gary S. (La Jolla CA) Greene Howard E. (Carlsbad CA), Immunometric assays using monoclonal antibodies.
Anne Katrin Werenskiold DE, In-vitro method for prognosticating the illness development of patients with carcinoma of the breast and/or for diagnosing carcinoma of the breast.
Snider, James V., Methods of treating or selecting a treatment for a subject having heart failure that include detecting levels of galectin-3 and soluble ST2.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.